CRS In Vitro Assay Services

CRS is a potentially life-threatening systemic inflammatory response that can occur following CAR-T cell infusion, characterized by excessive release of pro-inflammatory cytokines. Creative Biolabs' CRS In Vitro Assay Services are designed to quantitatively evaluate the cytokine storm potential of immunotherapies prior to clinical application. These assays stand out due to its high sensitivity, multiplex cytokine profiling capability, and use of distinct immune cells, ensuring clinically relevant and predictive data. By utilizing this service, you will gain critical insights into the safety profile of their therapeutic products, optimize CAR-T cell design to mitigate CRS risks, and accelerate the development of safer and more effective cell-based immunotherapies.

Introduction

Cytokines serve as pivotal mediators in CAR-T therapy, critically influencing T cell activation, persistence, and antitumor efficacy while also shaping the immunosuppressive tumor microenvironment. However, excessive or dysregulated cytokine activation can precipitate CRS, a systemic inflammatory response characterized by elevated levels of cytokines such as IL-6, IFN-γ, and GM-CSF, which may lead to life-threatening complications including vascular leakage, multi-organ dysfunction, and hemodynamic instability. Therefore, the implementation of robust CRS in vitro assays is essential for preclinically profiling cytokine storm risks, elucidating underlying immunopathological mechanisms, and guiding the development of targeted mitigation strategies to enhance both the efficacy and safety profile of cell-based immunotherapies.

Fig.1 CAR-T cell therapy-induced cytokine release syndrome: mechanisms and kinetics.¹

CRS In Vitro Assay Services at Creative Biolabs

Creative Biolabs' CRS In Vitro Assay Services utilize an optimized co-culture system combined with high-throughput multiplex assay technology to deliver comprehensive profiling of the dynamic release kinetics of key cytokines. Our services provide you with robust and reliable data to gain critical insights into the CRS risk profile of your candidate therapy, thereby enabling you to refine product design and enhance its safety. Moreover, we offer in vitro cytokine release assay service and in vitro cytotoxicity analysis service, please feel free to contact us for more information.

What We Can Offer

We provide a comprehensive suite of advanced in vitro assay platforms to systematically evaluate and de-risk CRS, enabling precise profiling of immune cell activation, cytokine storm dynamics, and safety assessment for cell therapies.

Our Service Process

Required starting materials:

• PBMC or target cell lines.
• Test agent.

Final Deliverables: We provide a comprehensive data report including raw data files and quantitative parameters report.

Key Advantages

• Precision Mechanistic Analysis: Routinely, we employ intracellular cytokine staining combined with the tracking of activation markers to accurately identify the cellular origin of toxic responses, yielding deeper mechanistic insights that cannot be obtained through multiplex cytokine assays alone.
• Targeted Signaling Pathway Analysis: We provide integrated testing solutions to systematically evaluate the inhibitory effects on key inflammatory signaling molecules while simultaneously monitoring the dynamic changes of critical chemokines, thereby supplying essential evidence for the development of effective intervention strategies.

FAQ

Why Choose Us?

In the field of immunotoxicity screening, we stand apart through our superior predictive power, dedicated to providing data packages of exceptional reliability and practical utility. We have moved beyond the traditional paradigm of cytokine detection by adopting high-resolution technologies and constructing models with direct translational relevance, thereby guaranteeing both precision and actionable insights in research outcomes.

Customer Reviews

"Using Creative Biolabs' CRS In Vitro Assay in our research has significantly improved our ability to resolve T-cell vs. NK-cell cytokine contribution via Intracellular Cytokine Staining. This level of mechanistic detail is impossible with standard ELISA and directly informed our lead selection."— Dr. K***ly N.

"We transitioned our CAR-T safety screening entirely to Creative Biolabs' autologous monocyte co-culture model after our internal PBMC assay failed to predict severe monocyte activation. Their model successfully isolated the IL-6 driven CRS signal, drastically de-risking our trials."— Ms. R***h S.

"Creative Biolabs provided a comprehensive data package that integrated quantitative IC50 values for key chemokines (CCL8, CXCL10). Their data quality is non-negotiable."— Prof. J***n M.

How to contact us?

Leveraging deep-seated scientific knowledge and cutting-edge technological platforms, we deliver bespoke solutions tailored to each project's unique requirements, ensuring objectives are not only met but surpassed. To explore how our expertise can advance your goals, we invite you to connect with our team.

Reference

1. Silveira, Caio Raony Farina et al. "Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications." Frontiers in immunology vol. 13 947648. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2022.947648.